BioVentrix said today that it won renewed German reimbursement for its Revivent TC transcatheter ventricular enhancement system.
The San Ramon, Calif.-based company said that the German Institute for Hospital Remuneration reconfirmed NUB 1 status for the Revivent TC device.
NUB 1 status allows participating hospitals to receive full reimbursement for the product and supplemental payments for using technologies not listed in the German healthcare system, BioVentrix said.
The Revivent system is designed to eliminate the need for cardiopulmonary bypass or incisions in the heart by enabling the placement of small titanium anchors along the heart’s outer surface and along one of the inside walls, the company said.
“Attaining NUB Reimbursement Status 1 for a third time is a testament to the impact Revivent TC is having in the German heart failure community. The number of hospitals applying for coverage of Less Invasive Ventricular Enhancement procedures with the Revivent TC system more than doubled. This large increase in product adoption demonstrates the existing therapy gap and growing need for clinically impactful, less invasive, and cost effective HF treatment options. We will continue to partner with German heart failure centers who wish to provide this novel therapy to patients who have limited options available to treat their left ventricular dysfunction,” prez & CEO Kenneth Miller said in a press release.
In October 2017, BioVentrix said that it enrolled the 1st US patient in a pivotal clinical trial of its Revivent TC transcatheter ventricular enhancement system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.